SEARCH

SEARCH BY CITATION

References

  • 1
    Morrow DA, Gersh BJ, Braunwald E. Chapter 50: chronic coronary artery disease in Braunwald’s Heart Disease. In: ZipesDP, LibbyP, BonowRO, BraunwaldE, eds. A Textbook of Cardiovascular Medicine, 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:12811354.
  • 2
    Marshall AJ, Heaton S, Barritt DW, et al. Dose response for blood pressure and degree of cardiac beta blockade with atenolol. Postgrad Med J. 1979;55:537540.
  • 3
    Palatnik A, Kates R. Bradycardia and medications identify the dangerous pace. Nurs Manage. 2003;34:56A56F.
  • 4
    Edoute Y, Nagachandran P, Svirski B, et al. Cardiovascular adverse drug reaction associated with combined beta adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol. 2000;35:556559.
  • 5
    Hartwell BL, Mark JB. Combinations of beta blockers and calcium channel blockers. Anesth Analg. 1986;65:905907.
  • 6
    Sagie A, Strasberg B, Kusnieck J, et al. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991;14:314316.
  • 7
    Andrivet P, Beaslay V, Kiger J-P, et al. Complete sinus arrest during diltiazem therapy; clinical correlates and efficacy of intravenous calcium. Eur Heart J. 1994;15:350354.
  • 8
    Brouwer RML, Follath F, Buhler FR. Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. J Cardiovasc Pharmacol. 1985;4:S38S44.
  • 9
    Wayne VS, Harper RW, Laufer E, et al. Adverse interaction between beta-adrenergic blocking drugs and verapamil – report of three cases. Aust N Z J Med. 1982;12:285289.
  • 10
    Mills TA, Kawji MM, Cataldo VD, et al. Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs. J La State Med Soc. 2004;156:327331.
  • 11
    Sakurai H, Kei M, Matsubara K, et al. Cardiogenic shock triggered by verapamil and atenolol. Jpn Circ J. 2000;64:893896.
  • 12
    Henry M, Kay MM, Viccellio P. Cardiogenic shock associated with calcium-channel and beta blockers. Am J Emerg Med. 1985;3:334336.
  • 13
    Mager A, Strasberg B, Rechavia E, et al. Clinical significance and predisposing factors to symptomatic bradycardia and hypotension after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1994;74:10851088.
  • 14
    Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. Blood Press. 1996;5:260263.
  • 15
    Rogers IR, Prpic R. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Med J Aust. 1998;169:425427.
  • 16
    Hassell AB, Creamer JE. Profound bradycardia after the addition of diltiazem to a beta blocker. BMJ. 1989;298:675.
  • 17
    Hedner T. Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol (Copenh). 1986;58(suppl 2):119130.
  • 18
    Lee JH, Ryu HM, Bae MH, et al. Prognosis and natural history of drug-related bradycardia. Korean Circ J. 2009;39:367371.
  • 19
    Chalmers JP, Smith SA, Wing MH. Hypertension in the elderly: the role of calcium antagonists. J Cardiovasc Pharmacol. 1988;12(suppl 8):S147S155.
  • 20
    Ahmed JH, Meredith PA, Elliott HL. The influence of age on the pharmacokinetics of verapamil. Pharmacol Res. 1991;24:227233.
  • 21
    Rosenthal T, Nussinovitch N. Managing hypertension in the elderly in light of the changes during aging. Blood Press. 2008;17:186194.
  • 22
    Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations. Drugs Aging. 1991;1:194211.
  • 23
    Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Cardiol Rev. 2007;15:195215.
  • 24
    Tregaskis BF, McDevitt DG. Beta-adrenoceptor-blocking drugs in the elderly. J Cardiovasc Pharmacology. 1990;16(suppl 5):S25S28.
  • 25
    Sabanathan K, Castleden CM, Adam HK, et al. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Pharmacol. 1987;32:5360.
  • 26
    Tjandramaga TB. Altered pharmacokinetics of beta-adrenoceptor blocking drugs in patients with renal insufficiency. Arch Int Pharmacodyn Ther. 1980;38(suppl):3853.
  • 27
    Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990;112:120125.
  • 28
    Shepherd G. Treatment of poisoning casued by beta-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63:18281835.
  • 29
    Carlberg B, Samuelsson O. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:16841689.
  • 30
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:573583.
  • 31
    Houston MC. Review article: clonidine hydrochloride. S Med J. 1982;75:713719.
  • 32
    Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med. 1987;82:1719.